Clinical trials: GEJ Adenocarcinoma
HNSCC, ESCC
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
- Conditions
- HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- NCT07182149
- Testing
- NRM-823
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- Normunity AccelCo, Inc.
Gastric Cancer, Esophagogastric Junction Cancer
A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of ONO-4578 in combination nivolumab and chemotherapy in participants with advanced or metastatic gastric cancer, esophagogastric junction cancer, or esophageal…
- Conditions
- Gastric Cancer, Esophagogastric Junction Cancer, Esophageal Adenocarcinoma
- Trial name
- NCT07818070
- Testing
- ONO-4578, Nivolumab, Oxaliplatin
- Volunteers
- 600 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory…
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT07284186
- Testing
- PLX-61639
- Where
- 10 sites in United States
- Volunteers
- 155 people
- Sponsor
- Plexium, Inc.
Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma
Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer
Multi-center, open-label, non-randomized Phase II study to evaluate the efficacy and safety of OSI-7904L in gastric and GEJ cancers.
- Trial name
- NCT00073502
- Testing
- OSI-7904L
- Where
- 11 sites in United States, Belgium and 1 more
- Volunteers
- 43 people
- Sponsor
- OSI Pharmaceuticals
Stomach Neoplasms
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil [FP regimen] or oxaliplatin combined with capecitabine [CAPOX regimen])…
- Trial name
- NCT03675737
- Testing
- Pembrolizumab, Cisplatin, 5-fluorouracil
- Where
- 215 sites in United States, Argentina and 31 more
- Volunteers
- 1,579 people
- Sponsor
- Merck Sharp & Dohme LLC
Adenocarcinoma Esophagus, Adenocarcinoma of the Stomach
Molecular Analysis of Gastric and OEsophageal Cancers STudy
A prospective translational tissue collection study to identify biomarkers predictive of treatment response/resistance and biomarkers of prognostic value from a series of patients who are investigated for and diagnosed with early…
- Conditions
- Adenocarcinoma Esophagus, Adenocarcinoma of the Stomach, Adenocarcinoma - GEJ, Squamous Cell Car. - Esophagus
- Trial name
- MAGnET (NCT06702384)
- Testing
- biopsy
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Gastric Cancer, Stomach Cancer
Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer
This study is to evaluate the efficacy and safety of addition of intraperitoneal (ip) Floxuridine to adjuvant chemoradiation therapy for patients under-going potentially curative stomach resection.
- Trial name
- NCT00858338
- Testing
- Potentially curative surgery, Floxuridine (IP), Adjuvant Chemoradiation therapy
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- NYU Langone Health
Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer
A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
The purpose of this study is to assess the safety, tolerability and antitumor activity of IMAB362 in Japanese subjects with locally advanced or metastatic Gastric or GEJ adenocarcinoma whose tumors have Claudin (CLDN) 18.2…
- Trial name
- NCT03528629
- Testing
- Zolbetuximab
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Astellas Pharma Inc
Gastric Adenocarcinoma
Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The primary objective of this study is to compare the efficacy of andecaliximab (GS-5745) versus placebo in combination with modified fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (OXA) (mFOLFOX6) as measured by overall…
- Trial name
- GAMMA-1 (NCT02545504)
- Testing
- Andecaliximab, Leucovorin, 5-fluorouracil
- Where
- 134 sites in United States, Australia and 14 more
- Volunteers
- 432 people
- Sponsor
- Gilead Sciences
Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancer
- Trial name
- NCT04309578
- Testing
- Trastuzumab, Capecitabine and Cisplatin
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Asan Medical Center
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
This is a multicenter, randomized, controlled, open-label study evaluating efficacy and safety of perioperative FLOT chemotherapy plus intraoperative HIPEC versus FLOT chemotherapy alone in patients with resectable localized and…
- Trial name
- PREVENT (NCT04447352)
- Testing
- 5-Fluorouracil, Leucovorin, Oxaliplatin
- Where
- 15 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Krankenhaus Nordwest
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur.
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04032704
- Testing
- ladiratuzumab vedotin, pembrolizumab
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 205 people
- Sponsor
- Seagen Inc.
Stomach Adenocarcinoma, Gastro-esophageal Junction Cancer
Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of the multimodal treatment, which includes radiotherapy, chemotherapy and anti-PD-1 immunotherapy. The trial is designed using a pick-the-winner strategy.
- Trial name
- TORCH-G (NCT06728657)
- Testing
- HFRT targeted to the primary lesion and positive lymph nodes, PULSAR targeted to the primary lesion and positive lymph nodes, Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
Advanced Solid Tumor
Study of SRF617 in Patients With Advanced Solid Tumors
A Phase 1, first-in-human, monotherapy and combination dose escalation and expansion study of SRF617.
- Trial name
- NCT04336098
- Testing
- SRF617, Gemcitabine, Albumin-Bound Paclitaxel
- Where
- 10 sites in United States, Canada
- Volunteers
- 85 people
- Sponsor
- Coherus Oncology, Inc.
Adenocarcinoma - GEJ, Gastric Adenocarcinoma
DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study
This phase II study evaluates dostarlimab followed by a watch-and-wait strategy in patients with localized dMMR/MSI-H gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Trial name
- DEWI (NCT06059495)
- Testing
- Dostarlimab
- Where
- 18 sites in France, Italy
- Volunteers
- 89 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Locally Advanced Gastric Adenocarcinoma
Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma
The effective treatment of G/GEJ adenocarcinoma has always been a research hotspot in academia. In recent years, mainstream studies have shown that the treatment mode of G/GEJ adenocarcinoma has changed from single surgery mode…
- Trial name
- NCT05507658
- Testing
- Tislelizumab combined with Oxaliplatin and Capecitabine
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Xijing Hospital
Gastric or Gastroesophageal Junction Adenocarcinoma
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
This is a multi-national, open-label, randomized, seamless phase II/III clinical study of UTD2 combined with fluoropyrimidine- and platinum-containing therapy to evaluate the efficacy and safety in patients with locally advanced…
- Trial name
- NCT06841679
- Testing
- Utidelone Capsule, Fluoropyrimidine- and Platinum-containing Therapy, Oxaliplatin
- Where
- 10 sites in United States, China
- Volunteers
- 778 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
The main purpose of this study was to evaluate the safety and pharmacokinetics of administering various dose regimens of ramucirumab in participants with advanced gastric cancer whose disease has progressed during or following…
- Trial name
- NCT02443883
- Testing
- Ramucirumab
- Where
- 45 sites in United States, Argentina and 10 more
- Volunteers
- 164 people
- Sponsor
- Eli Lilly and Company
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
This is a phase 2 multicenter study that will evaluate the safety and efficacy of sacituzumab tirumotecan (Sac-TMT) plus fruquintinib for the treatment of participants with locally advanced or metastatic gastric (G) or…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma
- Trial name
- SKB264-Fru-GA (NCT07689292)
- Testing
- Sacituzumab Tirumotecan + Fruquintinib
- Volunteers
- 45 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Cancer, Gastro Esophageal Junctional Cancer
IKS04 Regimen in Advanced Solid Tumors That Express CA242
This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify a recommended phase 2 dose (RP2D) or recommended dose for further…
- Conditions
- Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma
- Trial name
- NCT07738939
- Testing
- IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Iksuda Therapeutics Ltd.